Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

"Whether the modest trend in biochemical failure differences will sustain and translate into prostate cancer-specific or overall survival remains to be seen," he said. "We have be ...

Former President Joe Biden, aged 82, has begun radiation therapy for aggressive prostate cancer that has spread to his bones. Experts weigh in on what his prognosis may be and what the treatment path ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

Prostate cancer treatment could be "supercharged" by a new way of weakening malignant cells, say scientists in Australia.

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their ...

Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1’s consistent impact on cancer cell survival pathways. MIAMI, ...

This early stage is often detected through routine screenings, such as a prostate-specific antigen (PSA) blood test and a digital rectal exam (DRE), before any symptoms arise. Because the disease is ...

Many clinicians who treat men with prostate cancer may be unfamiliar with the term "treatment-emergent small-cell neuroendocrine prostate cancer" (t-SCNC). That's because it has been considered a rare ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...